Case Report of Skin Condition Linked to Cabozantinib
Author Information
Author(s): Rehan Zahra, Haner Andrea, Taleb Amina, Ikeri Nzechukwu, Hardin Jori
Primary Institution: Cumming School of Medicine, University of Calgary
Hypothesis
Is acquired reactive perforating collagenosis (ARPC) associated with Cabozantinib treatment?
Conclusion
The study presents a novel case of ARPC linked to Cabozantinib therapy, showing partial improvement with topical treatment after stopping the medication.
Supporting Evidence
- ARPC is a rare skin condition often linked to systemic diseases and certain medications.
- The patient had a history of diabetes and developed ulcers after starting Cabozantinib.
- Topical treatments were initiated after stopping Cabozantinib, leading to gradual improvement.
Takeaway
A woman developed a skin problem after taking a cancer drug called Cabozantinib, but her condition got better when she stopped the drug and used a special cream.
Methodology
Case report detailing the patient's history, symptoms, treatment, and follow-up.
Limitations
The findings are based on a single case report, limiting generalizability.
Participant Demographics
60-year-old female with metastatic clear cell carcinoma and a history of diabetes.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website